DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee

Information source: Ardabil University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoarthritis of the Knee

Intervention: Glucosamine and chondroitin sulfate (Drug); glucosamine and chondroitin sulfate plus Prednisolone (Drug); Glucosamine and Chondroitin sulfate plus Chloroquine (Drug); Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Ardabil University of Medical Sciences

Official(s) and/or principal investigator(s):
Shahab Bohlooli, PhD, Principal Investigator, Affiliation: Pharmacology Dept, Faculty of Medicine, ArdabilUMS
Marina Jastan, MD, Principal Investigator, Affiliation: Rheomatology clinic, Faculty of Medicine, ArdabilUMS

Summary

This study was conducted to evaluate the efficacy and safety of prednisolone and chloroquine add on therapies to combined glucosamine, chondroitin sulfate in osteoarthritis of the knee which will be done in contrast to combined glucosamine sulfate and chondroitin.

Clinical Details

Official title: Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee Treated With Fixed Dose Combination of Glucosamine and Chondroitin Sulfate.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome:

The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA)

The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA)

The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA)

Secondary outcome:

The secondary measure will be changes in stiffness

The secondary measure will be changes in stiffness

The secondary measure will be changes in stiffness

Detailed description: Fixed dose glucosamine, chondroitin sulfate combination is a treatment to osteoarthritis with some controversy about efficacy. it seems that addition of other agents may improve efficacy and decrease the required dose and cost. common oral corticosteroids such as low dose prednisolone and chloroquine are candidate for such add on therapies. nevertheless, add on therapy may expose the patients to new side effects which should followed and addressed. In this investigator blinded controlled trial, 240 patients with diagnosed osteoarthritis of knee will be enrolled to the study. the patients will randomly be assigned to one of four groups of G (glucosamine and chondroitin sulfate ), P (Glucosamine and Chondroitin sulfate plus Prednisolone), C (Glucosamine and Chondroitin sulfate plus Chloroquine) and PC (Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine). each group will consist 60 patients. the investigator(s) will be blind to the groups and interventions.

Eligibility

Minimum age: 40 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- men and non-pregnant women, age 40-85 years with primary OA of at least one knee.

Exclusion Criteria:

- secondary arthritis related to systemic inflammatory arthritis (including rheumatoid

arthritis, psoriatic arthritis, post-infectious arthritis and metabolic arthritis, traumatic arthritis or surgical joint replacement)corticosteroid use:

- oral corticosteroid within the previous 14 days

- intramuscular corticosteroid within 30 days

- intraarticular corticosteroid into the study knee within 90 days

- intra-articular corticosteroid into any other joint within 30 days or

- topical corticosteroid at the site of application within 14 days

- ongoing use of prohibited medication including NSAID, other oral analgesic, muscle

relaxant, or low-dose antidepressant for any chronic pain management

- glucosamine or chondroitin within the previous six months

- history of alcohol or drug abuse

- lactation

- concomitant skin disease at the application site

- current application for disability benefits on the basis of knee osteoarthritis;

fibromyalgia; other painful or disabling condition affecting the knee

Locations and Contacts

ArdabiUMS Clinic of Rheumatology, Ardabil 56197, Iran, Islamic Republic of
Additional Information

Starting date: February 2009
Last updated: April 29, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017